Renal Disease in Minority Populations and Developing Nations
A Satellite Meeting of the World Congress on Nephrology
Petropolis, Brazil
April 25 - 27, 2007

A CME Programme sponsored by :

Charles R. Drew University of Medicine and Science	Sociedale Brasileira de Nefrologia	International Society of Nephrology
Renal Caretec International Pte Ltd ----------------------------------------------------------

Charles R. Drew University of Medicine and Science designates this educational activity for a maximum of 15.5 AMA PRA Category 1 Credit(s) TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.

All physicians seeking CME credit are required to register on-site with the CME staff.
Charles R. Drew University of Medicine and Science College of Medicine
Office of Continuing Medical Education • 1731 E. 120th Street • Los Angeles , CA 90059
For more information regarding CME credits, please contact:
Rosie Marie Connor • rosieconnor@cdrewu.edu • 323-249-5714


Program Objectives
Upon completion of this conference participants will be able to:

•  Identify key strategies for improving the detection and prevention of CKD in developing nations and
   ethnic minority populations.
•  Summarize the newest findings on treatment and clinical outcome CKD in developing nations.
•  Describe the pathogenesis and pathophysiology of CKD in developing nations.
•  Cite the key risk factors that contribute to the worldwide CKD pandemic.
•  Recognize the need to design and/or support programs to reduce the rising incidence of CKD/ESRD
   in developing
   nations and ethnic minority populations.
•  Recognize new research opportunities for improving CKD/ESRD outcomes in developing nations.

Faculty Disclosure

As a sponsor accredited by the ACCME, Charles R. Drew University of Medicine and Science must insure balance, independence, objectivity, and scientific rigor in all its individually sponsored or jointly sponsored educational activities. All faculty participating in a sponsored activity are expected to disclose to the activity audience any significant financial interests or other relationship (1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of activity.

(Significant financial interest or other relationship can include such things as grants or research support, employee, consultant, major stock holder, member of speakers' bureau, etc.) The intent of this disclosure is not to prevent a speaker with significant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion.

The Policy on identification of products and for discussing unlabeled uses of products is described as follows. Generic and trade names: Presentations must give a balanced view of therapeutic options. Faculty use of generic names will contribute to this impartiality. If trade names are used those of several companies should be used rather than only that of a single supporting company. Unlabeled uses of products: When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the accredited provider shall require the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.